Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Operating Expenses (2016 - 2025)

Karyopharm Therapeutics' Operating Expenses history spans 14 years, with the latest figure at $51.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 16.01% year-over-year to $51.9 million; the TTM value through Dec 2025 reached $236.8 million, down 10.54%, while the annual FY2025 figure was $236.8 million, 10.54% down from the prior year.
  • Operating Expenses reached $51.9 million in Q4 2025 per KPTI's latest filing, down from $59.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $82.6 million in Q2 2022 to a low of $51.9 million in Q4 2025.
  • Average Operating Expenses over 5 years is $69.2 million, with a median of $67.4 million recorded in 2022.
  • The largest YoY upside for Operating Expenses was 18507.53% in 2021 against a maximum downside of 71.5% in 2021.
  • A 5-year view of Operating Expenses shows it stood at $79.3 million in 2021, then fell by 14.95% to $67.4 million in 2022, then rose by 6.09% to $71.6 million in 2023, then dropped by 13.6% to $61.8 million in 2024, then fell by 16.01% to $51.9 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Operating Expenses are $51.9 million (Q4 2025), $59.3 million (Q3 2025), and $62.3 million (Q2 2025).